Parkinson's disease: Focus on management alternatives

Author(s): Justice, L. N.

Journal/Book: Am J Manag Care. 2000; 6: 241 Forsgate Dr, Ste 102, Jamesburg, NJ 08831, USA. Amer Med Publishing, M W C Company. 93-113.

Abstract: AUDIENCE This activity is designed for physicians, pharmacists, nurses, health planners, directors of managed care organizations, and payers of health services. GOAL To understand the impact that Parkinson's disease has on Patients and to identify areas of drug therapy that can be optimized to improve a patient's quality of life. OBJECTIVES 1. Discuss the epidemiology and pathophysiology of idiopathic Parkinson's disease (IPD). 2. Identify causes of secondary parkinsonism and medications associated with drug-induced parkinsonism. 3. Discuss the cardinal and secondary manifestations of IPD. 4. Outline the 6 stages of IPD. 5. Identify therapeutic alternatives for various levodopa I treatment failures. 6. Identify the 3 newer antiparkinson agents and state their mechanisms of action, common adverse effects, drug interactions, and appropriate use. 7. Identify the appropriate use, common adverse effects, and drug interactions of dopamine agonists, anticholinergic agents, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors in Parkinson's disease therapy.

Note: Article Young LR, Univ Tennessee, Coll Pharm, 875 Monroe Ave, Suite 116, Memphis,TN 38163 USA

Keyword(s): MOTOR FLUCTUATIONS; DOUBLE-BLIND; CONTROLLED TRIAL; LEVODOPA; PRAMIPEXOLE; SELEGILINE; TOLCAPONE; PLACEBO; ROPINIROLE; MORTALITY

Zurück | Weiter